Form 4: Adicet Bio Director Carl Gordon Reverts Stock Options to Original Exercise Price
SEC Form 4 Filing
Director Carl L. Gordon reports changes in beneficial ownership of Adicet Bio, Inc. stock options due to the rescission of a prior repricing.
Summary
- Carl L. Gordon, a director and 10% owner of Adicet Bio, Inc., filed a Form 4 on August 23, 2024, reporting changes in his beneficial ownership of the company's stock options.
- On August 21, 2024, Adicet Bio's Board of Directors approved the rescission of the August 2023 stock option repricing for certain non-employee directors.
- As a result, Gordon's stock options were reverted to their original exercise prices as established at the time of the grant.
- The reported transactions include the disposal and acquisition of stock options with varying exercise prices and expiration dates.
- The shares subject to these options are fully vested and exercisable as of August 21, 2024.
Sentiment
Score: 6
Explanation: The document is neutral in tone, simply reporting required information about stock option adjustments. It doesn't contain overtly positive or negative information.
Positives
- The rescission of the stock option repricing could be seen as a positive move towards aligning director compensation with the company's long-term performance.
- The fact that the shares are fully vested and exercisable provides the director with immediate access to the potential benefits of the options.
Industry Context
This filing is a routine disclosure related to insider transactions and compensation adjustments, common in publicly traded companies. The rescission of the repricing could be related to shareholder feedback or changes in company policy.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Stock Option Repricing Rescission | The Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. | 08/21/2024 | All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. |
Stakeholder Impact
- Shareholders may view the rescission of the stock option repricing as a positive step towards aligning director compensation with company performance.
Key Dates
| Date | Description |
|---|---|
| 08/21/2024 | Date of the board approval of the rescission of the August 2023 stock option repricing. |
| 08/23/2024 | Date of the Form 4 filing. |
| 09/16/2030 | Expiration date of some of the stock options. |
| 04/29/2031 | Expiration date of some of the stock options. |
| 06/01/2032 | Expiration date of some of the stock options. |
| 05/31/2033 | Expiration date of some of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.